Hvor har du $15M fra? Tidligere pressemeldinger sier $100M + royalties.
January 8, 2020
Press release - Non-regulatory
- IOVaxis buys an exclusive option to license the TG01/02 cancer vaccines for China, Hong Kong, Macau and Singapore, for a fee of USD 250.000
- If exercised, the license has a potential value of up to USD 100 million in development and commercial milestones, in addition to double-digit royalties